40 patents
Utility
Methods of Treating Pulmonary Injury with CGRP Inhibitors
14 Sep 23
Provided is a method for treating COVID-19 in a patient in need of such treatment, wherein the method includes administration to the patient of a therapeutically effective amount of CGRP inhibitor.
St John Donnie McGrath, Vladimir CORIC, Charles M. CONWAY, Reese M. Caldwell, Steven M. SCHNITTMAN
Filed: 22 Mar 21
Utility
Prodrugs of Riluzole and Their Method of Use
29 Jun 23
Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole.
Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
Filed: 8 Sep 22
Utility
Oral Fast-dispersing Dosage Form of Rimegepant
6 Apr 23
Provided is a fast-dispersing dosage form for oral delivery, wherein the fast-dispersing dosage form includes a rimegepant.
Vladimir CORIC, Marianne FROST, Robert CROOP, Charles M. CONWAY
Filed: 26 Feb 21
Utility
CD16A binding agents and uses thereof
7 Feb 23
Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same.
Anna Bunin, Lawrence G. Iben, Douglas Manion, David Adam Spiegel, Matthew Ernest Welsch
Filed: 8 Jan 19
Utility
CD38-BINDING Agents and Uses Thereof
26 Jan 23
Among other things, the present disclosure provides compounds comprising antibody binding moieties and CD38-binding targeting moieties.
Luca RASTELLI, Matthew Ernest WELSCH, Anna BUNIN, Ann Marie K. ROSSI, Tetyana BERBASOVA
Filed: 24 Jun 20
Utility
Riluzole Prodrugs and Their Use
19 Jan 23
Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole.
Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
Filed: 5 Jul 21
Utility
Intranasal Pharmaceutical Compositions of CGRP Inhibitors
22 Dec 22
Provided is pharmaceutical composition for intranasal delivery, wherein the pharmaceutical composition includes a therapeutically active ingredient including a CGRP inhibitor.
Vladimir CORIC, Charles M. CONWAY, Robert CROOP, Rajesh KUMAR
Filed: 17 Dec 20
Utility
Prodrugs of Riluzole and Their Method of Use
15 Dec 22
Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole.
Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
Filed: 4 May 20
Utility
Molecules That Bind to TDP-43 for the Treatment of Amyotrophic Lateral Sclerosis and Related Disorders
8 Dec 22
Pharmaceutical compositions of the invention comprise TDP-43 binding agents having a disease-modifying action in the treatment of diseases associated with TDP-43 that include ALS, FTLD, CTE, hippocampal sclerosis of aging (CARTS), Alzheimer's disease, and Alzheimer's disease related disorder, and disease that involve excess amounts of TDP-43 in the cytosol.
Marianne CARLSEN, Garry R. SMITH, Randall J. BINDER, Camille REMEUR, Allen B. REITZ, Xiao JIN
Filed: 21 Aug 20
Utility
Prodrugs of riluzole and their method of use
13 Sep 22
Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole.
Garry Robert Smith, Allen B. Reitz, Mark McDonnell, Suzie Chen, Matthew D. Vera, Benjamin E. Blass, Jeffrey Claude Pelletier, Venkata N. Velvadapu, Jay Edward Wrobel
Filed: 23 Nov 20
Utility
Formulation for Oral Delivery of Proteins, Peptides and Small Molecules with Poor Permeability
11 Aug 22
The present disclosure is directed to a pharmaceutical formulation intended for oral delivery of synthetic or natural poorly permeable calcitonin gene-related peptide (CGRP) inhibitors or salts/solvates thereof having a therapeutic activity.
Vincent PLASSAT, Benoit HILBOLD, Aurélia GALUS, Thomas POINTEAUX, Julien MEISSONNIER, Gene M. DUBOWCHIK, Charles M. CONWAY
Filed: 10 Apr 20
Utility
Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
2 Aug 22
Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole.
Vladimir Coric
Filed: 19 May 17
Utility
Use of Riluzole Oral Disintigrating Tablets for Treating Diseases
14 Jul 22
Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof, in the form of an oral solid molded fast-dispersing dosage form.
Vladimir Coric, Robert Berman, Irfan Qureshi
Filed: 26 May 19
Utility
Prodrugs of lanicemine and their method of use
14 Jun 22
Pharmaceutical compositions of the invention include substituted Lanicemine prodrugs useful for the treatment of conditions associated with dysregulation of NMDA receptor activity such as depression and depressive disorders through the release of Lanicemine, Prodrugs of Lanicemine have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release Lanicemine in the plasma via either an enzymatic or general biophysical release process.
Allen B. Reitz, Jeffery Claude Pelletier
Filed: 22 Nov 17
Utility
Prodrugs of CGRP Antagonists
23 Dec 21
Disclosed are prodrugs of CGRP antagonists, methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof the prodrugs, pharmaceutical compositions comprising prodrugs and kits including the pharmaceutical compositions and instructions for use.
Charles M. Conway, Gene M. Dubowchik, Jeffrey Claude Pelletier, Allen B. Reitz
Filed: 10 Oct 19
Utility
CGRP Antagonists for Treating Migraine Breakthrough
4 Nov 21
Disclosed are methods of treating breakthrough migraine in patients using breakthrough CGRP antagonists.
Vladimir Coric, Robert Croop
Filed: 19 Jan 20
Utility
Use of Riluzole Oral Disintigrating Tablets for Treating Diseases
14 Oct 21
Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt or prodrug thereof, in the form of an oral solid molded fast-dispersing dosage form.
Vladimir Coric
Filed: 15 Aug 19
Utility
Use of Riluzole Prodrugs to Treat Alzheimer's Disease
23 Sep 21
Disclosed are methods of treating Alzheimer's Disease by administering to a patient in need thereof a riluzole prodrug such as troriluzole.
Vladimir Coric, Robert Berman, Irfan Qureshi
Filed: 20 Jul 19
Utility
Amine prodrugs of pharmaceutical compounds
10 Aug 21
Disclose are amine prodrugs and methods of synthesis thereof.
Anthony Marfat
Filed: 19 Aug 19
Utility
Rimegepant for CGRP related disorders
10 Aug 21
Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof.
Vladimir Coric, Robert Croop
Filed: 27 May 20